Figure 1.
Post-alloHCT Outcomes. (A) OS landmarked from the alloHCT date. Reprinted from Lancet Hematology7 with permission from Elsevier. (B) Subgroup analyses of OS landmarked from the alloHCT date. “N” denotes the number of patients who proceeded to alloHCT. One patient who achieved a best response of CR relapsed before alloHCT. (C) Cumulative incidence of relapse. (D) Cumulative incidence of NRM. CMML, chronic myelomonocytic leukemia; HMA, hypomethylating agent.

Post-alloHCT Outcomes. (A) OS landmarked from the alloHCT date. Reprinted from Lancet Hematology7  with permission from Elsevier. (B) Subgroup analyses of OS landmarked from the alloHCT date. “N” denotes the number of patients who proceeded to alloHCT. One patient who achieved a best response of CR relapsed before alloHCT. (C) Cumulative incidence of relapse. (D) Cumulative incidence of NRM. CMML, chronic myelomonocytic leukemia; HMA, hypomethylating agent.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal